Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 12, 2001

View Archived Issues

Licensing opportunity from NIH: novel posttranscriptional regulatory elements

Licensing opportunity from NIH: acridine derivative for overcoming MDR

Gilead reports product and pipeline highlights for 2000

Nicotine replacement therapy business of Aventis acquired by Pharmacia

Alza acquires Flexeril product and trademark from Merck & Co.

ARGENT technology demonstrates potential in prostate cancer

Medarex and Seattle Genetics to jointly develop human antibody therapeutics

NCX-530 is less toxic than indomethacin to the intestine according to rat studies

Highly potent HIV protease inhibitors from Tibotec may prevent class-wide crossresistance

Magainin and Ludwig Institute further their gene/protein-based alliance

Inhibitor of HIV-1 Rev function acts on receptor-mediated export

Kinetic and clinical data presented in Chicago support further development of DAPD

Approvable letter issued by FDA for GlaxoSmithKline's Avandia in combination with insulin

LDP-02 enters phase II in Canada for ulcerative colitis

Next-generation NNRTI advances to clinical testing in HIV-infected subjects

Second-generation HIV protease inhibitors retain activity against highly resistant strains

KS Biomedix's KSB-301 enters phase II for osteoarthritis

Promising preclinical data reported for Isotechnika immunosuppressant in type 1 diabetes

First oral chemotherapy for treatment of metastatic colorectal cancer approved in Europe

Antisense modulators of integrin beta3 expression

Isis designs antisense oligonucleotides that modulate the expression of G-proteins

Cationic peptides with antibacterial activity described by Canadian university

Novel series for diabetes and related disorders emerges from Tularik-JT collaboration

Panacos and collaborators discuss preclinical profile of anti-HIV candidate

Aventis presents new antibacterial agents derived from moenomycin A

European patent issued to Pfizer for new opioid receptor antagonists

Heterocyclic inhibitors of tyrosine kinase-mediated signal transduction

Kissei and Purdue Pharma terminate licensing agreement for mitiglinide

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...